Status:
COMPLETED
The ATLANTA First in Man Study of the Catania Stent
Lead Sponsor:
CeloNova BioSciences, Inc.
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE1
Brief Summary
To evaluate the short-term and mid-term safety and efficacy of the Catania coronary stent for the treatment of up to two de novo lesions in native coronary arteries.
Detailed Description
This is a prospective, non-randomized, first-in-man single center study. The study requires a 55 patients with documented myocardial ischemia undergoing PCI.
Eligibility Criteria
Inclusion
- Lesion length ≤ 20 mm
- Vessel size ≥ 2.5 ≤ 3.5 mm
Exclusion
- Life expectancy \< 1 year
- Left ventricular ejection fraction (LVEF) \<30%
- Anti-thrombotic drug intolerance
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00799032
Start Date
May 1 2007
End Date
August 1 2008
Last Update
June 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ferrarotto Hospital
Catania, Sicily, Italy, 95124